Sunitinib and other targeted therapies for renal cell carcinoma

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

(2010) A A M van der Veldt et al.   BRITISH JOURNAL OF CANCER

Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma

(2010) John D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

Alterations in VHL as potential biomarkers in renal-cell carcinoma

(2010) Lucy Gossage et al.   Nature Reviews Clinical Oncology

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

(2009) Loukas F Kontovinis et al.   BMC CANCER

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

(2009) Brett E. Houk et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

(2009) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY

Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma ≤ 1 cm Is Not Justified

(2009) Amod A. Sarnaik et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma

(2009) Thomas E. Hutson et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma

(2009) M.P. Sablin et al.   JOURNAL OF UROLOGY

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

(2009) Martin E Gore et al.   LANCET ONCOLOGY

Resistance to targeted therapy in renal-cell carcinoma

(2009) Brian I Rini et al.   LANCET ONCOLOGY

Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease

(2008) Peter Valent   BRITISH JOURNAL OF HAEMATOLOGY

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

(2008) Robert J. Motzer et al.   CANCER

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma

(2008) Olwen M. Hahn et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

(2007) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY